騰盛博藥-B(02137.HK)公佈年度業績，研發開支達4.95億元
格隆匯3月23日丨騰盛博藥-B(02137.HK)發佈公吿，截至2021年12月31日止年度，其他收入為人民幣9900萬元，與上年度相比，增加人民幣1440萬元或17.0%。該增加的主要原因是所確認來自中國政府補貼的收入增加。該年度研發開支為人民幣4.946億元。
作為一家致力於減輕全球公共衞生負擔的公司，集團專注於促進重大傳染病和中樞神經系統(“CNS”)疾病(尤其是抑鬱症)的治療，集團的主要業務在中國和美國。公司自2017年成立以來，已採取多項措施執行戰略，力爭成為專注公共衞生行業，具有強大的研發、業務開發及商業化能力的全面一體化全球生物製藥公司。集團已成立具有強大產品研發及轉化研究能力的內部團隊，同時已建立享有全球權利的專有候選產品管線。公司的內部研發及外部合作的雙引擎可促進其靈活的跨國業務模式，為患者開發有效的療法。在尋找可行治療方法時，集團已建立超過10項涵蓋關於乙型肝炎病毒(“HBV”)、人類免疫缺陷病毒(“HIV”)、新型冠狀病毒肺炎(“COVID-19”)及產後抑鬱症╱重度抑鬱症(“PPD/MDD”)的臨牀試驗的多樣化產品管線。
報吿期間，在業務戰略的指導下，集團已實現多個重大臨牀開發里程碑，並將尋求更多突破。在集團基於RNA干擾治療的獨特聯合療法設計的推動下，HBV功能性治癒療法乃集團的重中之重。集團為實現HBV功能性治癒的臨牀開發在中國是最先進的，而中國是全球最大的HBV市場。集團於中國進行的BRII-835 (VIR-2218)的2期單藥治療研究的安全性及抗病毒活性結果預期於2022年第一季度獲得。最近，集團於2022年2月完成BRII-835 (VIR-2218)/BRII-179 (VBI-2601)聯合療法2期研究的患者入組，共計90名分別來自新西蘭、澳大利亞、新加坡、中國香港、中國台灣、韓國及泰國的患者。為進一步鞏固集團在HBV研發的領導地位，集團已制定一條於2022年推進HBV項目的清晰路徑。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
